EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders

Akshay Bedmutha, Michal Weiler-Sagie, Leen Alkukhun, Amol Madan Takalkar

PET Clinics · 2027-01 · 22 (1) · 141-158

DOI: 10.1016/j.cpet.2026.06.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2027-01. Verfasst von Akshay Bedmutha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Multiple Myeloma. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) serves a multifaceted role across nonlymphoma hematolymphoid disorders, though its utility varies considerably by disease entity. In multiple myeloma, FDG-PET/CT is the International Myeloma Working Group-preferred imaging modality for response assessment, with standardized interpretation through Italian Myeloma criteria for PET Use/Deauville criteria enabling reproducible evaluation. PET-based complete metabolic response and dual imaging-plus-minimal residual disease negativity provide the strongest prognostic stratification, validated across landmark trials including CASSIOPEIA and FORTE. Important limitations include nonavid disease and inferior sensitivity for diffuse marrow infiltration compared to WB-MR imaging, where evidence for combined FDG-PET/MR imaging is gathering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRadiopharmaceuticalsMultiple MyelomaLymphoproliferative DisordersHumans

Stichwörter der Autor:innen

FDG PET/CTMultiple myelomaNonlymphomatous hematolymphoid disordersResponse assessment

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA.
  • Nuclear Medicine Department, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA. Electronic address: amol.madan.takalkar@emory.edu.

Zitieren

APA

Bedmutha, A., Weiler-Sagie, M., Alkukhun, L., & Takalkar, A. M. (2027). Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders. PET Clinics, 22(1), 141-158. https://doi.org/10.1016/j.cpet.2026.06.019

Vancouver

Bedmutha A, Weiler-Sagie M, Alkukhun L, Takalkar AM. Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders. PET Clinics. 2027;22(1):141-158. doi:10.1016/j.cpet.2026.06.019

BibTeX
@article{Bedmutha2027,
  author = {Bedmutha, Akshay and Weiler-Sagie, Michal and Alkukhun, Leen and Takalkar, Amol Madan},
  title = {Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders},
  journal = {PET Clinics},
  year = {2027},
  volume = {22},
  number = {1},
  pages = {141--158},
  doi = {10.1016/j.cpet.2026.06.019}
}
Kostenlos starten →